Burden of disease associated with cervical cancer in Malaysia and potential costs and consequences of HPV vaccination

Asian Pacific Journal of Cancer Prevention

Volumn 11, Issue 6, 2010, Pages 1551-1559

  Aljunid, S ^a   Zafar, A ^a   Saperi, S ^a   Amrizal, M ^a  

^a UNIVERSITI KEBANGSAAN MALAYSIA MEDICAL CENTER   (Malaysia)

Author keywords

Cervical cancer burden; HPV vaccination; Malaysia

Indexed keywords

EID: 79956115440     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. American Cancer Society. Detailed Guide: cervical cancer. Available at: http://www.cancer.org/docroot/cri/content/cri_2_4_1x_what_are_the_key_statistics_for_cervical_cancer_8.asp [Last accessed June 03, 2010]
2. Bergeron C, Largeron N, McAllister R, et al (2008). Costeffectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France. Int J Technol Assess Health Care, 24, 10-9.
3. Bosch FX, Lorincz A, Muñoz N, et al (2002). The causal relation between human papillomavirus and cervical cancer. J Clin Pathol, 55, 244-65.
4. Brown DR, Kjaer SK, Sigurdsson K, et al (2009). The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis, 199, 926-35.
5. Canfell K, Sitas F, Beral V (2006). Cervical cancer in Australia and the United Kingdom: comparison of screening policy and uptake, and cancer incidence and mortality. Med J Aust, 185, 482-6.
6. th International Meeting of the European Society of Gynaecological Oncology, Belgrade, Serbia October 11-14.
7. Castellsague X, de Sanjose S, Aguado T, et al (2007). HPV and cervical cancer in the world: 2007 report. Vaccine, 25, C1-26.
8. Chow SN, Soon R, Park JS, et al (2010). Knowledge, attitudes, and communication around human papillomavirus (HPV) vaccination amongst urban Asian mothers and physicians. Vaccine, Mar 25. [Epub ahead of print]
9. David MP, Van Herck K, Hardt K, et al (2009). Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses. Gynecol Oncol, 115, S1-6.
10. de Sanjosé S, Diaz M, Castellsagué X, et al (2007). Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis, 7, 453-9.
11. Dunne EF, Unger ER, Sternberg M, et al (2007). Prevalence of HPV infection among females in the United States. JAMA, 297, 813-9.
12. Einstein MH, Baron M, Levin MJ, et al (2009). HPV-010 study group. Comparison of the immunogenicity and safety of cervarix and gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin, 5, 705-19.
13. Ferlay J, Shin HR, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, [EPub ahead of print].
14. Fleury MJ, Touzé A, Alvarez E, et al (2006). Identification of type-specific and cross-reactive neutralizing conformational epitopes on the major capsid protein of human papillomavirus type 31. Arch Virol, 151, 1511-23.
15. FUTURE II Study Group (2007). Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med, 356, 1915-27.
16. Garland SM, Cuzick J, Domingo EJ, et al (2008). Recommendations for cervical cancer prevention in Asia Pacific. Vaccine, 26, M89-98.
17. Garland SM, Hernandez-Avila M, Wheeler CM, et al (2007). FUTURE I investigators. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med, 356, 1928-43.
18. Goldie SJ, Kohli M, Grima D, et al (2004). Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst, 96, 604-15.
19. Harper DM, Franco EL, Wheeler CM, et al (2006). HPV Vaccine Study group. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet, 367, 1247-55.
20. Health Facts (2008). Health Informatics Centre Planning and Development Division. Ministry of Health Malaysia (Published in May 2009) Available at: http://www.moh.gov.my/images/gallery/stats/heal_fact/health_fact_2008_page_by_page.pdf [Last accessed June 03, 2010]
21. Huh WK (2009). Impact of quadrivalent human papillomavirus (hpv) types 6/11/16/18 l1 virus-like particle vaccine on the incidence of abnormal pap tests and cervical procedures. (Abstract number 020 presented at the society of gynecologic oncologists (sgo) annual meeting on women's cancer, 9 -12 March, 2009, Tampa, U.S.A.)
22. Insinga RP, Dasbach EJ, Myers ER (2003). The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis, 36, 1397-403.
23. Lukasiewicz E, Aractingi S, Flahault A (2002). Incidence and management of condylomata accuminata by French general physicians. Ann Dermatol Venereol, 129, 991-6.
24. Liu PH, Hu FC, Lee PI, et al (2010). Cost-effectiveness of human papillomavirus vaccination for prevention of cervical cancer in Taiwan. BMC Health Serv Res, 10, 11.
25. Malaysian National Cancer Registry (2006). Malaysian cancer statistics data and figures Malaysian Peninsula.
26. Marur S, D'Souza G, Westra WH, et al (2010). HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol, 11, 781-9.
27. Muñoz N, Kjaer SK, Sigurdsson K, et al (2010). Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst, 102, 325-39.
28. Othman NH, Rebolj M (2009). Challenges to cervical screening in a developing country: the case of Malaysia. Asian Pac J Cancer Prev, 10, 747-52.
29. Paavonen J, Naud P, Salmerón J, et al (2009). HPV PATRICIA study group. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomized study in young women. Lancet, 374, 301-14.
30. Rebolj M, van Ballegooijen M, Berkers LM, et al (2007). Monitoring a national cancer prevention program: successful changes in cervical cancer screening in the Netherlands. Int J Cancer, 120, 806-12.
31. Roteli-Martins CM, Naud P, Borba P, et al (2010). Sustained immunogenicity and efficacy of the HPV 16/18 AS04 adjuvanted vaccine: follow up of up to 8.4 years. Abstract presented at European society for pediatric infectious diseases meeting May 2010, Nice, France.
32. Sam IC, Wong LP, Rampal S, et al (2009). Maternal acceptance of human papillomavirus vaccine in Malaysia. J Adolesc Hlth, 44, 610-2.
33. Sanders GD, Taira AV (2003). Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis, 9, 37-48.
34. Sharifah Ezat WP, Aljunid SA, Ng P, et al (2009). Quality of life among preinvasive and invasive cervical cancer in Malaysia. ASEAN J Psychiatry, 10, 1-11.
35. Simms I, Fairley CK (1997). Epidemiology of genital warts in England and Wales: 1971 to 1994. Genitourin Med, 73, 365-7.
36. Skinner R, Apter D, Chow SN, Wheeler C, Dubin G, for the HPV PATRICIA Study Group(2009). Cross-protective efficacy of Cervarix™ against oncogenic HPV types beyond HPV-16/18. Abstract number O-29.01. presented at the 25th International Papillomavirus Conference, May 8-14, Malmö, Sweden
37. Smith JS, Lindsay L, Hoots B, et al (2007). Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer, 121, 621-32.
38. Stanley M (2008). Human papillomavirus vaccines versus cervical cancer screening. Clin Oncol (R Coll Radiol), 20, 388-94.
39. Suarez E, Smith JS, Bosch XF, et al (2008). Cost-effectiveness of vaccination against cervical cancer: a multi-regional analysis assessing the impact of vaccine characteristics and alternative vaccination scenarios. Vaccine, 26S, F29-45.
40. Szarewski A (2010). HPV vaccine: Cervarix. Expert Opin Biol Ther, 10, 477-87.
41. Taira AV, Neukermans CP, Sanders GD (2004). Evaluating human papillomavirus vaccination programs. Emerg Infect Dis, 10, 1915-23.
42. Tjalma W, Paavonen J, Naud P, et al. Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against abnormal cytology and low-grade histopathological lesions in an oncogenic hpvnaïve population. (Abstract number A-171-0004-01446 presented at the 16th international meeting of the European society for gynaecological oncology (ESGO), 11-14 Oct, Belgrade, Serbia).
43. Third National Health and Morbidity Survey. Available at: www.nih.gov.my/NHMS.
44. Wheeler CM, Kjaer SK, Sigurdsson K, et al (2009). The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis, 199, 936-44.
45. WHO/ICO Information Centre on Human Papilloma Virus (HPV) and Cervical Cancer. Available at: http://www.who.int/hpvcentre/en/ [Last accessed July 02, 2010]
46. WHO GLOBOCAN 2002 database - summary table by population. Available at: http://globocan.iarc.fr/. [Last accessed: September 13, 2010]
47. Wong LP, Wong YL, Low WY, et als (2009). Knowledge and awareness of cervical cancer and screening among Malaysian women who have never had a Pap smear: a qualitative study. Singapore Med J, 50, 49-53.